Last 48 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Standard BioTools Inc.'s quarterly P/E stands at 0.7x.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.87 | 0.70 | 6.39 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.54 | 4.22 | 38.24 | 6.36 | 5.25 | 2.50 | 3.51 | 3.99 | 7.33 | 4.38 | 1.56 | 2.26 | 1.37 |
| — | +68.5% | +990.3% | +59.5% | -28.4% | -42.8% | +124.4% | +76.2% | +433.9% | +185.1% | +81.7% | +167.4% | -17.2% | |
| P/B Ratio | 0.70 | 0.64 | 1.16 | 1.24 | 1.08 | 0.90 | 1.39 | 1.47 | 1.29 | 1.38 | 1.08 | — | — |
| — | -29.2% | -16.4% | -15.1% | -16.7% | -34.9% | +28.7% | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Standard BioTools Inc.'s operating margin was -59.1% in Q1 2026, up 287.6 pp QoQ and up 21.7 pp YoY. The trailing four-quarter average of -161.0% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 10.5% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.9% | 53.5% | 83.5% | 48.5% | 48.8% | 48.4% | 46.9% | 51.7% | 46.1% | 53.1% | 47.4% | 44.0% | 49.2% |
| — | +10.5% | +78.1% | -6.2% | +5.9% | -8.9% | -1.1% | +17.6% | -6.2% | +8.6% | +14.7% | +22.3% | +108.5% | |
| Operating Margin | -109.3% | -59.1% | -346.7% | -120.0% | -118.1% | -80.8% | -70.2% | -70.5% | -134.5% | -132.2% | -75.9% | -83.5% | -63.1% |
| — | +26.9% | -393.6% | -70.2% | +12.2% | +38.8% | +7.4% | +15.5% | -113.3% | -100.1% | +2.9% | +26.3% | +69.3% | |
| Net Margin | -87.8% | 600.9% | 598.5% | -177.4% | -153.7% | -63.8% | -72.9% | -59.9% | -203.3% | -70.6% | -70.2% | -82.8% | -61.6% |
| — | +1041.7% | +920.6% | -196.2% | +24.4% | +9.6% | -4.0% | +27.6% | -230.0% | -5.3% | +9.1% | +27.9% | +81.8% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.7% | 25.8% | 4.7% | -8.4% | -7.6% | -5.6% | -7.1% | -5.4% | -8.4% | -8.7% | -125.6% | — | — |
| — | +558.8% | +166.0% | -56.2% | +9.5% | +35.3% | +94.4% | — | — | — | — | — | — | |
| ROA | -12.7% | 21.1% | 3.5% | -6.3% | -5.9% | -4.4% | -5.3% | -3.9% | -6.2% | -5.8% | -6.0% | -6.0% | -4.7% |
| — | +582.1% | +166.1% | -63.3% | +4.3% | +25.2% | +11.8% | +35.9% | -31.3% | -32.2% | -15.3% | +12.1% | +73.7% | |
| ROIC | -20.7% | -2.8% | -2.6% | -5.9% | -6.1% | -7.3% | -7.0% | -6.8% | -6.4% | -15.3% | -32.7% | — | — |
| — | +61.4% | +62.1% | +12.6% | +3.8% | +51.8% | +78.7% | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 102.0% YoY to 12.36x, strengthening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.05 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.18 | 0.18 | 0.16 | 0.60 | — | — |
| — | -24.2% | +3.9% | -62.5% | -62.0% | -56.4% | -88.4% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.19 | 12.36 | 4.19 | 4.38 | 5.16 | 6.12 | 5.70 | 3.76 | 3.88 | 4.50 | 1.45 | 3.30 | 3.91 |
| — | +102.0% | -26.5% | +16.4% | +33.1% | +35.8% | +294.2% | +14.1% | -0.8% | +1.2% | -69.9% | -33.6% | -33.4% | |
| Quick Ratio | 4.01 | 11.92 | 4.01 | 4.14 | 4.92 | 5.37 | 5.09 | 3.41 | 3.53 | 4.17 | 1.26 | 2.87 | 3.44 |
| — | +122.0% | -21.2% | +21.5% | +39.1% | +28.7% | +303.9% | +18.6% | +2.8% | +6.0% | -70.8% | -35.9% | -35.6% | |
| Interest Coverage | -3718.31 | — | -3866.20 | -3289.00 | -2030.33 | -13091.00 | — | — | -28.61 | -30.01 | -17.16 | -14.32 | -13.45 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LAB stock.
Standard BioTools Inc.'s current P/E is -3.9x. The average P/E over the last 2 quarters is 3.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Standard BioTools Inc.'s current operating margin is -109.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Standard BioTools Inc.'s business trajectory between earnings reports.